These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 18480167)

  • 1. The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy.
    Pérez-Molina JA; Domingo P; Martínez E; Moreno S
    J Antimicrob Chemother; 2008 Aug; 62(2):234-45. PubMed ID: 18480167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen.
    Autar RS; Boyd MA; Wit FW; Ruxrungthams K; Sankote J; Lange J; Cooper DA; Phanuphak P; Burger DM; Reiss P
    Antivir Ther; 2007; 12(8):1265-71. PubMed ID: 18240866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching to darunavir/ritonavir monotherapy vs. triple-therapy on body fat redistribution and bone mass in HIV-infected adults: the Monarch randomized controlled trial.
    Guaraldi G; Zona S; Cossarizza A; Vernacotola L; Carli F; Lattanzi A; Nardini G; Orlando G; Garlassi E; Termini R; Garau M
    Int J STD AIDS; 2014 Mar; 25(3):207-12. PubMed ID: 24216034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).
    Negredo E; Miró O; Rodríguez-Santiago B; Garrabou G; Estany C; Masabeu A; Force L; Barrufet P; Cucurull J; Domingo P; Alonso-Villaverde C; Bonjoch A; Morén C; Pérez-Alvarez N; Clotet B;
    Clin Infect Dis; 2009 Sep; 49(6):892-900. PubMed ID: 19663689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid metabolism and lipodystrophy in HIV-1-infected patients: the role played by nonnucleoside reverse transcriptase inhibitors.
    Sension M; Deckx H
    AIDS Rev; 2015; 17(1):21-36. PubMed ID: 25472015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine.
    Bernardino JI; Pulido F; Martinez E; Arrizabalaga J; Domingo P; Portilla J; Ocampo A; Muñoz J; Torres R; Arribas JR;
    J Antimicrob Chemother; 2013 Jun; 68(6):1373-81. PubMed ID: 23386261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of nucleoside reverse transcriptase inhibitors in the fat redistribution syndrome.
    Nolan D; Mallal S
    J HIV Ther; 2004 May; 9(2):34-40. PubMed ID: 15238874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Body-fat abnormalities in patients with HIV: progress and challenges.
    Bedimo RJ
    J Int Assoc Physicians AIDS Care (Chic); 2008; 7(6):292-305. PubMed ID: 19056708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study.
    Young J; Rickenbach M; Weber R; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
    Antivir Ther; 2005; 10(1):73-81. PubMed ID: 15751765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous toxicities of antiretroviral therapy for HIV: part I. Lipodystrophy syndrome, nucleoside reverse transcriptase inhibitors, and protease inhibitors.
    Introcaso CE; Hines JM; Kovarik CL
    J Am Acad Dermatol; 2010 Oct; 63(4):549-61; quiz 561-2. PubMed ID: 20846563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.
    Haubrich RH; Riddler SA; DiRienzo AG; Komarow L; Powderly WG; Klingman K; Garren KW; Butcher DL; Rooney JF; Haas DW; Mellors JW; Havlir DV;
    AIDS; 2009 Jun; 23(9):1109-18. PubMed ID: 19417580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Body fat distribution in HIV-infected patients treated for 96 weeks with darunavir/ritonavir monotherapy versus darunavir/ritonavir plus nucleoside reverse transcriptase inhibitors: the MONOI-ANRS136 substudy.
    Valantin MA; Kolta S; Flandre P; Algarte Genin M; Meynard JL; Ponscarme D; Slama L; Cuzin L; de Kerviler E; Inaoui R; Katlama C
    HIV Med; 2012 Sep; 13(8):505-15. PubMed ID: 22416798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of an anti-retroviral combination regimen including either efavirenz or lopinavir-ritonavir with a backbone of two nucleoside reverse transcriptase inhibitors.
    Panagopoulos P; Tsiodras S; Antoniadou A; Katsarolis I; Papadopoulos A; Poulakou G; Giamarellou H
    Clin Microbiol Infect; 2006 May; 12(5):486-9. PubMed ID: 16643529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial.
    Sutinen J; Walker UA; Sevastianova K; Klinker H; Häkkinen AM; Ristola M; Yki-Järvinen H
    Antivir Ther; 2007; 12(1):97-105. PubMed ID: 17503753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen.
    Fischl MA; Collier AC; Mukherjee AL; Feinberg JE; Demeter LM; Tebas P; Giuliano M; Dehlinger M; Garren K; Brizz B; Bassett R
    AIDS; 2007 Jan; 21(3):325-33. PubMed ID: 17255739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "Bullfrog neck," a unique morphologic trait in HIV lipodystrophy: case series and review of the literature.
    Tierney EP; Hanke CW
    Arch Dermatol; 2010 Nov; 146(11):1279-82. PubMed ID: 21079066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current concepts of metabolic abnormalities in HIV patients: focus on lipodystrophy.
    Kolter DP
    AIDS Read; 2003 Dec; 13(12 Suppl):S5-13. PubMed ID: 14959694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antiretroviral treatments-related lipodystrophy syndrome: clinico-pathological findings].
    Lassalle S; Cervera P; Hofman V; Mari M; Dellamonica P; Hofman P
    Ann Pathol; 2005 Sep; 25(4):309-17. PubMed ID: 16327657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
    Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
    HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of switching antiretroviral therapy on lipodystrophy and other metabolic complications: a review.
    Hansen BR; Haugaard SB; Iversen J; Nielsen JO; Andersen O
    Scand J Infect Dis; 2004; 36(4):244-53. PubMed ID: 15198179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.